{"id":"NCT01466062","sponsor":"AbbVie (prior sponsor, Abbott)","briefTitle":"Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions","officialTitle":"Multi-center, Open-label, Uncontrolled Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-08","primaryCompletion":"2012-04","completion":"2012-04","firstPosted":"2011-11-07","resultsPosted":"2013-06-17","lastUpdate":"2013-06-17"},"enrollment":28,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Respiratory Syncytial Virus Infection"],"interventions":[{"type":"DRUG","name":"Palivizumab","otherNames":["ABT-315","Synagis"]}],"arms":[{"label":"Palivizumab","type":"EXPERIMENTAL"}],"summary":"To evaluate safety, efficacy and pharmacokinetics of palivizumab in children at the age of 24 months or less with immunocompromised medical conditions.","primaryOutcome":{"measure":"Serum Palivizumab Trough Concentrations at Day 1, Day 31, and Day 121","timeFrame":"Day 1 (Screening), Day 31, Day 121","effectByArm":[{"arm":"Palivizumab","deltaMin":0,"sd":0}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":6,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["http://dailymed.nlm.nih.gov/dailymed/about.cfm"]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":28},"commonTop":["Upper Respiratory Tract Infection","Eczema","Gastroenteritis","Influenza","Hypogammaglobulinaemia"]}}